RxDoctor Payments Data

Evan Brittain, MD

Cardiovascular Disease · Nashville, TNNPI 1104020684

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,129 of the $11,079 with a category attached, or 91.4%. 4 manufacturers reported payments, led by Bayer at 58.0% of the total.

$11,079in general payments, 2019–2025

Across 15 payments — averaging $738.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$6K
  • Anumana, Inc.$3K
  • United Therapeutics Corporation$2K
  • Abbott$20
$455,112in research payments, 2019–2025

Across 34 payments — averaging $13,386 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$444K
  • Cumberland Pharmaceuticals, Inc.$7K
  • Siemens Medical Solutions USA, Inc.$4K

What the payments were for

  • Consulting fees$10,12991%
  • Travel & lodging$7136%
  • Food & beverage$2372%

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer11$6,430
Anumana, Inc.1$2,500
United Therapeutics Corporation2$2,129
Abbott1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,079 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$4,520
Medicare patients
110
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$11,238
Potassium Chloride14$753
Nifedipine ErNifedipine11$171
Spironolactone17$166

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →